CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 31 enrolled
Drug / intervention
Panitumumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00658658
NCT00658658Phase 1Completed
CompareCT.gov

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors

Amgen·interventional·Posted Apr 15, 2008·Updated May 18, 2016

In Brief

A Phase 1 clinical trial evaluating Panitumumab for Solid Tumors. Completed, enrolled 31 participants across 11 sites.

Detailed Summary

The primary objective of this study was to evaluate the safety and pharmacokinetics of up to 3 different dose schedules of panitumumab in pediatric patients with solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 15, 2008
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 18.2 years ago

Interventions

Panitumumabbiological

Panitumumab administered by intravenous infusion